Top Markets
Coin of the day
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc.

AMBS
Classifica tra le azioni #41182
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Prezzo delle azioni
$0.0001
Ultima sincronizzazione: 2026-08-11
Capitalizzazione di mercato
$36.84K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-66.67%
Paese
US
Scambia Amarantus BioScience Holdings, Inc. (AMBS)

Categoria

Il prezzo AMBS con la capitalizzazione del mercato della B
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
AMBS
$0.0001
Capitalizzazione di mercato di Amarantus BioScience Holdings, Inc.(AMBS)
Capitalizzazione di mercato: $36.84K
A partire dal August 2026, Amarantus BioScience Holdings, Inc. ha una capitalizzazione di mercato pari a $36.84K. Questo rende Amarantus BioScience Holdings, Inc. la 41182nd azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Amarantus BioScience Holdings, Inc. dal 2010 al 2026
AMBS in paragone con la classifica dei più popolari stocks
Il prezzo per AMBS Attivo B Capitalizzazione del mercato a B Risultati
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$14,612.41 $36.84K
$5.383T +14,612,413,949.56%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$12,006.71 $36.84K
$4.423T +12,006,707,654.24%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$11,292.77 $36.84K
$4.160T +11,292,769,909.18%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$9,943.60 $36.84K
$3.663T +9,943,597,622.65%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$7,847.86 $36.84K
$2.891T +7,847,856,351.78%